Xencor (XNCR) Cash from Investing Activities (2013 - 2026)
Xencor's (XNCR) quarterly Cash from Investing Activities came in at $26.7 million in Q1 2026, up 95.18% year-on-year from $13.7 million in Q1 2025, and down 62.52% on a QoQ basis from $71.2 million in Q4 2025.
Xencor (XNCR) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Cash from Investing Activities data on file, last reported at $26.7 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 95.18% year-over-year to $26.7 million in Q1 2026; TTM through Mar 2026 was $153.0 million, a 676.86% increase from a year earlier, with the FY2025 full-year figure at $140.0 million, up 1878.26% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $26.7 million, down from $71.2 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for XNCR reached as high as $71.2 million in Q4 2025 and fell as low as -$203.1 million in Q4 2023.
- Historically, Cash from Investing Activities has averaged -$4.2 million across 5 years, with a median of $24.5 million in 2022.
- Across the five-year window, Cash from Investing Activities plunged 927.48% in 2023 and surged 4798.65% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at $24.5 million in 2022, then plunged by 927.48% to -$203.1 million in 2023, then jumped by 128.18% to $57.3 million in 2024, then climbed by 24.32% to $71.2 million in 2025, then plunged by 62.52% to $26.7 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $26.7 million in Q1 2026, $71.2 million in Q4 2025, and $14.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Xencor | 1.49 Bn | 1.11 Bn | - | 26.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.68 Mn |
| Mar 31, 2026 | 26.68 Mn |
| Dec 31, 2025 | 71.17 Mn |
| Dec 31, 2025 | 71.17 Mn |
| Sep 30, 2025 | 14.67 Mn |
| Sep 30, 2025 | 14.67 Mn |
| Jun 30, 2025 | 40.48 Mn |
| Jun 30, 2025 | 40.48 Mn |
| Mar 31, 2025 | 13.67 Mn |
| Mar 31, 2025 | 13.67 Mn |
| Dec 31, 2024 | 57.25 Mn |
| Dec 31, 2024 | 57.25 Mn |
| Sep 30, 2024 | -163.46 Mn |
| Sep 30, 2024 | -163.46 Mn |
| Jun 30, 2024 | 66.02 Mn |
| Jun 30, 2024 | 66.02 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Dec 31, 2023 | -203.13 Mn |
| Dec 31, 2023 | -203.13 Mn |